General MedicationsINJECTIONStandard
KISUNLA
DONANEMAB-AZBT
Standard Dose
350MG/20ML(17.5MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview KISUNLA is listed in Drugs@FDA under application 761248 (BLA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient DONANEMAB-AZBT Form and strength INJECTABLE;INJECTION - 350MG/20ML(17.5MG/ML) Sponsor ELI LILLY CO Submission history Latest submission status date: 2025-07-01 00:00:00.
Structured Monograph
Clinical summary
Approval overview KISUNLA is listed in Drugs@FDA under application 761248 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient DONANEMAB-AZBT Form and strength INJECTABLE;INJECTION - 350MG/20ML(17.5MG/ML) Sponsor ELI LILLY CO Submission history Latest submission status date: 2025-07-01 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.